Hepatocellular carcinoma risk in patients with chronic hepatitis B receiving tenofovir- vs. entecavir-based regimens: Individual patient data meta-analysis
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Choi, Won-Mook | - |
dc.contributor.author | Yip, Terry Cheuk-Fung | - |
dc.contributor.author | Wong, Grace Lai-Hung | - |
dc.contributor.author | Kim, W. Ray | - |
dc.contributor.author | Yee, Leland J. | - |
dc.contributor.author | Brooks-Rooney, Craig | - |
dc.contributor.author | Curteis, Tristan | - |
dc.contributor.author | Cant, Harriet | - |
dc.contributor.author | Chen, Chien-Hung | - |
dc.contributor.author | Chen, Chi-Yi | - |
dc.contributor.author | Huang, Yi-Hsiang | - |
dc.contributor.author | Jin, Young-Joo | - |
dc.contributor.author | Jun, Dae Won | - |
dc.contributor.author | Kim, Jin-Wook | - |
dc.contributor.author | Park, Neung Hwa | - |
dc.contributor.author | Peng, Cheng-Yuan | - |
dc.contributor.author | Shin, Hyun Phil | - |
dc.contributor.author | Shin, Jung Woo | - |
dc.contributor.author | Yang, Yao-Hsu | - |
dc.contributor.author | Lim, Young-Suk | - |
dc.date.accessioned | 2023-10-04T06:41:14Z | - |
dc.date.available | 2023-10-04T06:41:14Z | - |
dc.date.created | 2023-03-08 | - |
dc.date.issued | 2023-03 | - |
dc.identifier.issn | 0168-8278 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/hanyang/handle/2021.sw.hanyang/191627 | - |
dc.description.abstract | Background & Aims: The comparative risk of hepatocellular carcinoma (HCC) in patients with chronic hepatitis B (CHB) receiving tenofovir disoproxil fumarate (TDF) vs. entecavir (ETV) remains controversial. In this individual patient data (IPD) meta-analysis, we aimed to compare HCC risk between the two drugs and identify subgroups who may benefit more from one treatment than the other. Methods: Published meta-analyses, electronic databases and congress proceedings were searched to identify eligible studies through January 2021. We compared HCC risk between the two drugs using a multivariable Cox proportional hazards model with anonymised IPD from treatment-naive patients with CHB receiving TDF or ETV for >-1 year. Treatment effect consistency was explored in propensity score matching (PSM), weighting (PSW) and subgroup analyses for age, sex, hepatitis B e-antigen (HBeAg) positivity, cirrhosis and diabetes status. Results: We included 11 studies from Korea, Taiwan and Hong Kong involving 42,939 patients receiving TDF (n = 6,979) or ETV (n = 35,960) monotherapy. Patients receiving TDF had significantly lower HCC risk (adjusted hazard ratio [HR] 0.77; 95% CI 0.61-0.98; p = 0.03). Lower HCC risk with TDF was consistently observed in PSM (HR 0.73; 95% CI 0.59-0.88; p <0.01) and PSW (HR 0.83; 95% CI 0.67-1.03; p = 0.10) analyses and in all subgroups, with statistical significance in the >-50 years of age (HR 0.76; 95% CI 0.58-1.00; p <0.05), male (HR 0.74; 95% CI 0.58-0.96; p = 0.02), HBeAg-positive (HR 0.69; 95% CI 0.49-0.97; p = 0.03) and non-diabetic (HR 0.79; 95% CI 0.63-1.00; p <0.05) subgroups. Conclusion: TDF was associated with significantly lower HCC risk than ETV in patients with CHB, particularly those with HBeAg positivity. Longer follow-up may be needed to better define incidence differences between the treatments in various subgroups. | - |
dc.language | 영어 | - |
dc.language.iso | en | - |
dc.publisher | Elsevier B.V. | - |
dc.title | Hepatocellular carcinoma risk in patients with chronic hepatitis B receiving tenofovir- vs. entecavir-based regimens: Individual patient data meta-analysis | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Jun, Dae Won | - |
dc.identifier.doi | 10.1016/j.jhep.2022.12.007 | - |
dc.identifier.scopusid | 2-s2.0-85147363831 | - |
dc.identifier.wosid | 000953493700001 | - |
dc.identifier.bibliographicCitation | Journal of Hepatology, v.78, no.3, pp.534 - 542 | - |
dc.relation.isPartOf | Journal of Hepatology | - |
dc.citation.title | Journal of Hepatology | - |
dc.citation.volume | 78 | - |
dc.citation.number | 3 | - |
dc.citation.startPage | 534 | - |
dc.citation.endPage | 542 | - |
dc.type.rims | ART | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
dc.description.isOpenAccess | Y | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Gastroenterology & Hepatology | - |
dc.relation.journalWebOfScienceCategory | Gastroenterology & Hepatology | - |
dc.subject.keywordPlus | adult | - |
dc.subject.keywordPlus | age | - |
dc.subject.keywordPlus | Article | - |
dc.subject.keywordPlus | cancer patient | - |
dc.subject.keywordPlus | cancer risk | - |
dc.subject.keywordPlus | chronic hepatitis B | - |
dc.subject.keywordPlus | comparative effectiveness | - |
dc.subject.keywordPlus | controlled study | - |
dc.subject.keywordPlus | cumulative incidence | - |
dc.subject.keywordPlus | diabetes mellitus | - |
dc.subject.keywordPlus | female | - |
dc.subject.keywordPlus | Hong Kong | - |
dc.subject.keywordPlus | human | - |
dc.subject.keywordPlus | Korea | - |
dc.subject.keywordPlus | liver cell carcinoma | - |
dc.subject.keywordPlus | liver cirrhosis | - |
dc.subject.keywordPlus | male | - |
dc.subject.keywordPlus | meta analysis | - |
dc.subject.keywordPlus | middle aged | - |
dc.subject.keywordPlus | monotherapy | - |
dc.subject.keywordPlus | patient coding | - |
dc.subject.keywordPlus | propensity score | - |
dc.subject.keywordPlus | risk assessment | - |
dc.subject.keywordPlus | sex | - |
dc.subject.keywordPlus | systematic review | - |
dc.subject.keywordPlus | Taiwan | - |
dc.subject.keywordPlus | treatment duration | - |
dc.subject.keywordPlus | liver cell carcinoma | - |
dc.subject.keywordPlus | liver tumor | - |
dc.subject.keywordPlus | retrospective study | - |
dc.subject.keywordPlus | treatment outcome | - |
dc.subject.keywordAuthor | Chronic hepatitis B | - |
dc.subject.keywordAuthor | entecavir | - |
dc.subject.keywordAuthor | hepatocellular carcinoma | - |
dc.subject.keywordAuthor | individual patient data | - |
dc.subject.keywordAuthor | meta-analysis | - |
dc.subject.keywordAuthor | tenofovir disoproxil fumarate | - |
dc.identifier.url | https://www.sciencedirect.com/science/article/pii/S0168827822034596?via%3Dihub | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
222, Wangsimni-ro, Seongdong-gu, Seoul, 04763, Korea+82-2-2220-1365
COPYRIGHT © 2021 HANYANG UNIVERSITY.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.